The OJ of the Ministry of Health published a Notice of the Minister of Health dated October 20, 2023 on the list of reimbursed drugs, foodstuffs for special nutritional purposes and medical devices for November 1, 2023.
REFUND NOTICE NO. 72 (NOVEMBER 1, 2023).
From the beginning of 2023, public funding will cover 145 new molecules and indications, including:
- 75 molecule - oncology indications,
- 70 molecule - non-oncology indications,
- 43 molecule - indications dedicated to rare diseases.
The reimbursement notice effective November 1, 2023 (No. 72) has been prepared in accordance with the new regulations effective November 1 regarding the determination of limit bases and the calculation of wholesale and retail margins. Compared to Announcement 71, it contains the following changes:
- A total of 78 products or new indications were added to the list due to positive reimbursement decisions.
- Reductions in official selling prices were introduced for 65 products (from PLN 0.01 to PLN 4,590.27).
- Official selling prices were increased for 69 products (from PLN 0.51 to PLN 2,430.00).
- For 994 items in the notice, the patient's co-payment will fall (from PLN 0.01 to PLN 452.70).
- For the 2,886 items in the notice, the patient surcharge will increase (from PLN 0.01 to PLN 157.41).
- Gross retail prices will be reduced for 70 products (from PLN 0.04 to PLN 197.18).
- For 4215 products, gross retail prices will increase (from PLN 0.05 to PLN 91.92).
- Due to the receipt of applications to shorten the term of reimbursement decisions, or the expiration of the term of reimbursement decisions or refusal of reimbursement for the next period, the announcement will not include 49 products or indications listed in the previous announcement.
INFORMATION ON THE LACK OF REIMBURSEMENT OF THE DRUGS FORXIGA, INVOKANA, FLUENZ TETRA ... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
If you already have an account, please log in
